Fjarde AP Fonden increased its stake in Bristol Myers Squibb (NYSE:BMY) by 21.5% during the first quarter, purchasing an additional 105,200 shares to hold a total of 595,006 shares valued at approximately $36 million. This move aligns with other major institutional investors who also expanded...
Wall Street Zen upgraded Bristol Myers Squibb (NYSE:BMY) to a 'strong-buy' rating, joining a mixed consensus of eight buy ratings, ten holds, and one sell. The stock currently trades with an average analyst target price of $61.31, reflecting varied sentiment among major institutions including recent...
Bristol-Myers Squibb (BMY) is currently trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company has declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record...
Bristol-Myers Squibb (BMY) stock is currently trading at $56.24, reflecting a mixed performance with a year-to-date return of 5.2% and a recent 90-day decline of 5.81%. The company has recently expanded its kidney cancer trial, the ROSETTA RCC-208 study, through a clinical collaboration with Arcus...
C4 Therapeutics stock rallied on Friday, reaching a 52-week high after Bristol-Myers Squibb released positive late-stage clinical trial data for its new treatment targeting multiple myeloma, a type of blood cancer. C4 shares surged due to the similarity between Bristol-Myers' drug and C4's own lead...
